采用EVL或TIPS治疗肝硬化并发食管静脉曲张出血患者疗效及其预后分析*

doi:10.3969/j.issn.1672-5069.2021.05.006

摘要/Abstract

摘要： 目的探讨采用食管曲张静脉套扎术(EVL)和经颈静脉肝内门体分流术(TIPS)治疗肝硬化并发食管曲张静脉破裂出血(EVB)患者的疗效。方法 2016年10月～2018年10月我院收治的74例肝硬化并发EVB患者,其中34例接受EVL治疗,另40例接受TIPS治疗,术后均随访2年。结果入组患者在急性出血被控制后,行EVL或TIPS治疗,均止血成功;在治疗后2 w,两组肝功能和血象变化无显著性差异(P＞0.05);术后,EVL治疗的肝硬化并发EVB患者胸腹痛、恶心和发热等并发症发生率88.2%,显著高于TIPS处理组(40.0%,P＜0.05);在2年的随访期间,术后两组患者EV再出血发生率比较,无显著性差异(41.2%对35.0%,P＞0.05); EVL治疗组病死率为20.6%,与TIPS治疗组的10.0%比,无显著性差异(P＞0.05)。结论采用EVL和TIPS均可作为治疗EVB的方法,但与EVL术相比,行TIPS治疗的肝硬化并发EVB患者并发症发生率更低,值得进一步研究。

关键词: 肝硬化, 食管曲张静脉破裂出血, 食管曲张静脉套扎术, 经颈静脉肝内门体分流术, 治疗

Abstract: Objective The aim of this study was to observe the efficacy of esophageal variceal ligation (EVL) and transjugular intrahepatic portosystemic shunt (TIPS) in treatment of patients with liver cirrhosis (LC) and esophageal varices bleeding (EVB). Methods 74 patients with LC complicated by EVB were admitted to our hospital between October 2016 and October 2018, and the EVL was carried out in 34 cases and the TIPS was performed in 40 patients. All patients were followed-up for 2 years. Results The EVL and TIPS were successfully completed in our patients after emergent hemostasis; at the end of two weeks, there was no significant difference as respect to liver function index or peripheral blood parameters in the two groups (P＞0.05); the incidences of post-operational complications in EVL-treated patients was 88.2%, much higher than 40.0% in TIPS-intervened patients (P＜0.05); during the two-year follow-up, the incidences of post-operational re-bleeding of esophageal varices were not significantly different between the two groups (41.2% vs. 35.0%, P＞0.05); the fatality rate in EVL-treated patients was 20.6%, not significantly different compared to 10.0% in patients who received TIPS (P＞0.05). Conclusion The efficacy of EVL and TIPS in dealing with patients with EVB is similar, while taking the post-operational complications into consideration, we recommend the latter for priority, which warrants further investigation.

Key words: Liver cirrhosis, Esophageal varices bleeding, Esophageal variceal ligation, Transjugular intrahepatic portosystemic shunt, Therapy

李伟, 宋卫东, 谢巴图白音. 采用EVL或TIPS治疗肝硬化并发食管静脉曲张出血患者疗效及其预后分析^*[J]. 实用肝脏病杂志, 2021, 24(5): 629-632.

Li Wei, Song Weidong, Xie Batu Baiyin. Efficacy of esophageal variceal ligation and transjugular intrahepatic portosystemic shunt in treatment of patients with liver cirrhosis and esophageal varices bleeding[J]. Journal of Practical Hepatology, 2021, 24(5): 629-632.

参考文献

[1]De Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol, 2015,63(3):743-752.
[2]Holster IL, Tjwa ET, Moelker A, et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + β-blocker for prevention of variceal rebleeding. Hepatology, 2016,63(2):581-589.
[3]赵长青,吕靖,徐列明.肝硬化并发门静脉血栓的研究进展. 中华肝脏病杂志,2019,27(12):933-937.
[4]Rush B, Deol N, Teriyaki A, et al. Lower 90-day hospital readmission rates for esophageal variceal bleedingafter TIPS: A nationwide linked analysis. J Clin Gastroenterol, 2020,54(1):90-95.
[5]赵洪伟,齐瑞兆,岳振东, 等.3367例经颈静脉肝内门体分流术的技术难点分析. 中华消化外科杂志, 2016,15(7):689-695.
[6]Dueñas E, Cachero A, Amador A, et al. Ulcer bleeding after band ligation of esophageal varices: Risk factors and prognosis. Dig Liver Dis, 2020,52(1):79-83.
[7]郭雅丽,徐宝宏,刘贤, 等.食管静脉曲张内镜治疗术后早期再出血的危险因素分析. 中华消化内镜杂志, 2018,35(2):89-93.
[8]中华医学会肝病学分会.肝硬化腹水及相关并发症的诊疗指南.实用肝脏病杂志,2018,21(1):21-31.
[9]中华医学会肝病学分会、消化病学分会、内镜学分会.肝硬化门静脉高压食管胃静脉曲张出血的防治指南. 实用肝脏病杂志,2016,19(5):Ⅰ-ⅩⅤⅠ.
[10] 林国帅,徐琴,赵淑一, 等.肝硬化并发门静脉血栓形成的临床特点及其相关危险因素分析.中华肝脏病杂志, 2016,24(7):513-517.
[11] Ueda C, Yosizaki T, Katayama N, et al. Barrett's adenocarcinoma with esophageal varices successfully treated by endoscopic submucosal dissection with direct varices coagulation. Clin J Gastroenterol, 2020,13(2):178-181.
[12] Tantemsapya N, Superina R, Wang D, et al. Hepatic histology and morphometric measurements in idiopathic extrahepatic portal vein thrombosis in children, correlated to clinical outcome of meso-rex bypass. Ann Surg, 2018,267(6):1179-1184.
[13] Wang YM, Li YH, Wu HM, et al. Portal vein thrombosis in patients with cirrhosis undergoing elective transjugular intrahepatic portosystemic shunt: risk factors, warfarin efficacy, and clinical outcomes. Clin Appl Thromb Hemost, 2018,24(3):462-470.
[14] 李莹,练晶晶,罗添成, 等.预防肝硬化食管静脉曲张再出血的成本效果研究.中华消化杂志, 2016,36(2):113-118.
[15] Kuo YH, Wu IP, Wang JH, et al. The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis. Invest New Drugs, 2018,36(2):307-314.
[16] Jakab SS, Garcia-Tsao G. Screening and surveillance of varices in patients with cirrhosis. Clin Gastroenterol Hepatol, 2019,17(1):26-29.
[17] 陈志娟,司毅,金瑞, 等.经颈静脉肝内门体分流术联合胃左静脉栓塞术治疗肝硬化食管胃底静脉曲张破裂出血初步临床研究.实用肝脏病杂志, 2017,20(2):238-239.
[18] Luo X, Wang Z, Tsauo J, et al. Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of tips versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology, 2015,276(1):286-293.
[19] Wang Z, Jiang MS, Zhang HL, et al. Is post-tips anticoagulation therapy necessary in patients with cirrhosis and portal vein thrombosis? A randomized controlled trial. Radiology, 2016,279(3):943-951.
[20] Nagaoki Y, Aikata H, Daijyo K, et al. Efficacy and safety of edoxaban for treatment of portalvein thrombosis following danaparoid sodium in patients with liver cirrhosis. Hepatol Res, 2018,48(1):51-58.

采用EVL或TIPS治疗肝硬化并发食管静脉曲张出血患者疗效及其预后分析^*

Efficacy of esophageal variceal ligation and transjugular intrahepatic portosystemic shunt in treatment of patients with liver cirrhosis and esophageal varices bleeding

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	汤磊, 邹桂舟. 外科疾病导致的胆源性肝损伤诊治现状[J]. 实用肝脏病杂志, 2021, 24(6): 769-771.
[2]	姜浩, 张雯, 陈霞. 长效干扰素联合利巴韦林治疗慢性丙型肝炎患者疗效及其对静息能量消耗和营养状态的影响^*[J]. 实用肝脏病杂志, 2021, 24(6): 815-818.
[3]	黄飞虎, 薛建亚, 朱咏梅, 余姣, 王丽艳, 鲁琼. 应用索磷布韦/维帕他韦治疗门诊和住院筛查的丙型肝炎患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(6): 819-822.
[4]	肖金玉, 王延峰, 文小霞. 自身免疫性肝炎患者血清趋化因子CCL4和CXCL10水平及其临床意义探讨[J]. 实用肝脏病杂志, 2021, 24(6): 827-830.
[5]	杜云飞, 刘景瑞, 叶飞翔. N-乙酰半胱氨酸联合双环醇治疗抗结核药物所致的药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2021, 24(6): 847-850.
[6]	吴晓枫, 黄怡, 杨如杏, 邓少东, 张静莹, 官成浓, 王颖. 原发性胆汁性肝硬化患者外周血丝氨酸蛋白酶抑制剂A1基因多态性分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 855-858.
[7]	石翠翠, 刘彦君, 章瑞南, 李光明, 范建高. 肝硬化患者血脂异常分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 859-862.
[8]	柳梅, 时永红, 郇娟, 陈茂丽. 失代偿期肝硬化患者并发医院内感染病原菌类别及其耐药特点分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 863-866.
[9]	刘玉玲, 甄增国, 王慧娟, 万秀敏, 郭振凯. 益生菌制剂对肝硬化并发自发性细菌性腹膜炎患者肠道屏障功能的影响^*[J]. 实用肝脏病杂志, 2021, 24(6): 867-870.
[10]	邢莉, 杜倩影, 姜艳丽, 韩冬. 分段注射对比剂CT增强扫描提高乙型肝炎肝硬化患者肝静脉显影效果研究^*[J]. 实用肝脏病杂志, 2021, 24(6): 871-874.
[11]	黄力鸥, 吴春荣, 徐丹, 崔宇慧, 唐建国. 无肝素化连续性肾脏替代治疗肝硬化并发肝性脑病患者疗效研究^*[J]. 实用肝脏病杂志, 2021, 24(6): 875-878.
[12]	叶东, 张俊霞, 李洁, 刘颖, 张丹, 郭永泽. 内镜下食管静脉曲张套扎术治疗乙型肝炎肝硬化并发食管胃底静脉曲张破裂出血患者再出血风险观察^*[J]. 实用肝脏病杂志, 2021, 24(6): 879-882.
[13]	韩成美, 韩永峰, 王春华. 乙型肝炎肝硬化患者并发急性肾损伤危险因素分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 883-886.
[14]	王菁, 毕宁, 方亮, 田园. 自体骨髓干细胞经肝动脉肝内移植治疗失代偿期乙型肝炎肝硬化患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(6): 887-890.
[15]	薛魁, 徐银海, 张健. 慢性乙型肝炎和乙型肝炎肝硬化患者血清血小板生成素水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2021, 24(6): 891-894.